(UroToday.com) Prostate cancer is the most common cancer diagnosed in US men. It is also the second leading cause of cancer-related mortality among US men. The incidence of advanced metastatic disease increased significantly between the years 2010 until 2014. Data has historically shown that survival in all stages of the disease was always lower for black men than for white men.
In this presented poster, the authors used data from the national program of cancer registries (NPCR) survival data, which includes 93% of US population coverage from 42 States and the District of Columbia. The authors calculated the five-year relative cancer specific-survival in the absence of other causes of death. The cohort that was analyzed included men with prostate cancer aged 40 and above with cancer diagnosed between the years 2001 and 2015 with follow up until 2015. Survival estimates were calculated and stratified by race ethnicity and year of diagnosis.
During 2001-2015, more than 2.8 million cases were recorded. The overall five-year relative survival was 97.7%. More than 2.2 million cases with localized disease were recorded with a 100% survival rate in all races and time periods. When comparing the time period of 2001 to 2007 to the time period of 2008 to 2015 for distant-stage disease, the overall survival improved from 29% to 31.3% and for disease with an unknown stage, the over survival improved from 83.4% to 84.7%.
Table 1 demonstrates the case distribution stratified by stage and race, and Figure 1 depicts the five-year relative survival of prostate cancer by race.
Table 1 — Case distribution by stage and race:
Figure 1 — 5-year relative survival of prostate cancer:
The authors concluded that 5-year survival was 100% for localized disease and >=97% for regional disease. Importantly, survival improved for regional, distant, and unknown stage. For distant-stage disease, survival was the highest in Hispanic men, followed by Black and White men.
The authors plan to further investigate the diagnosis patterns and clinical characteristics of men with distant and unknown cancer stage. This important research could inform interventions that might be required to address disparities in outcomes.
Presented by: David Siegel, MD, MPH, Medical Officer, Centers for Disease Control and Prevention, Atlanta, Georgia
Written by: Hanan Goldberg, MD, MSc., Urology Department, SUNY Upstate Medical University, Syracuse, NY, USA, @GoldbergHanan at the 2020 American Society of Clinical Oncology Virtual Annual Meeting (#ASCO20), May 29th-May 31st, 2020